Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.36 |
| ▸ | JAK1 | P23458 | 11/20 | 0.36 |
| ▸ | TYK2 | P29597 | 11/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | FEN1 | P39748 | 5/20 | 0.34 |
| ▸ | ULK1 | O75385 | 4/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613029 | 0.76 | FEN1 (0.39) | FEN1ULK1 | |
| SCHEMBL25625964 | 0.76 | ULK1 (0.48) | JAK2ULK1 | |
| SCHEMBL15599340 | 0.76 | CSNK2A1 (0.36) | JAK2JAK1TYK2JAK3FEN1 | |
| SCHEMBL13604904 | 0.75 | CDK8 (0.39) | FEN1ULK1 | |
| SCHEMBL25613062 | 0.75 | JAK3 (0.39) | JAK2JAK1JAK3FEN1ULK1 | |
| SCHEMBL25613433 | 0.74 | FEN1 (0.36) | FEN1ULK1 | |
| SCHEMBL25613171 | 0.73 | RIPK1 (0.39) | FEN1ULK1 | |
| SCHEMBL25613108 | 0.73 | ULK1 (0.39) | FEN1ULK1 | |
| SCHEMBL25613025 | 0.73 | FEN1 (0.37) | FEN1ULK1 | |
| SCHEMBL25613026 | 0.73 | FEN1 (0.42) | FEN1ULK1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | JAK2 431/4885JAK1 3603/4885TYK2 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.